IMRX Immuneering Corporation
Immuneering Corporation (IMRX) is expected to report earnings on November 4, 2026, before the market open. The consensus earnings estimate is a loss of $0.31 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +13.5% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Immuneering Corporation
Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process.
Sector
Healthcare
Industry
Biotechnology